MON-195 Decubitus Ulcer Prevention With Hormone Therapy: An Observational Finding

Disclosure: C. Dominguez-Bali: None. W.K. Massah: None. M.A. Bencomo: None. E. Johnson: None. H.A. Goraya: None. K. McCoy: None. M.A. Syed: None. R. Polam: None. E.S. Tsehaye: None. A. Dominguez-Bali: None. Hormone therapy (HT) has been largely discontinued among elderly populations following the release of the Women’s Health Initiative (WHI) study, primarily due to misinformation. However, a small number of elderly and centenarian women continue to use systemic and local HT. Interestingly, these individuals appear more resistant to developing decubitus ulcers, even after prolonged immobility. This study explores the potential link between HT and the prevention of decubitus ulcers in elderly female patients undergoing hormone therapy in homecare settings, with a particular focus on the vasodilatory effects of HT. It is hypothesized that HT effects may reduce the risk of hypoxia, ischemia, and tissue necrosis in pressure-prone areas. The findings provide a new perspective on HT that has not been addressed in the current literature. Women receiving both systemic and local HT demonstrated a significant reduction in decubitus pressure ulcer occurrence despite extended periods of immobilization. This observation was an accidental finding in several homecare facilities in which our team, taking care of patients, discovered in just 11 women we found receiving HRT over 90 years old in a time period of 7 years. While the use of HT remains a topic of debate, these findings suggest that its vasodilatory benefits could play a valuable role in geriatric care by reducing the risk of pressure ulcers in elderly women with limited mobility. Presentation: Monday, July 14, 2025